Literature DB >> 28968765

A framework for estimating and testing qualitative interactions with applications to predictive biomarkers.

Jeremy Roth1, Noah Simon1.   

Abstract

An effective treatment may only benefit a subset of patients enrolled in a clinical trial. We translate the search for patient characteristics that predict treatment benefit to a search for qualitative interactions, which occur when the estimated response-curve under treatment crosses the estimated response-curve under control. We propose a regression-based framework that tests for qualitative interactions without assuming linearity or requiring pre-specified risk strata; this flexibility is useful in settings where there is limited a priori scientific knowledge about the relationship between features and the response. Simulations suggest that our method controls Type I error while offering an improvement in power over a procedure based on linear regression or a procedure that pre-specifies evenly spaced risk strata. We apply our method to a publicly available dataset to search for a subset of HER2+ breast cancer patients who benefit from adjuvant chemotherapy. We implement our method in Python and share the code/data used to produce our results on GitHub (https://github.com/jhroth/data-example).

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28968765      PMCID: PMC6192465          DOI: 10.1093/biostatistics/kxx038

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  19 in total

1.  Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes, Part I: main content.

Authors:  Liliana Orellana; Andrea Rotnitzky; James M Robins
Journal:  Int J Biostat       Date:  2010       Impact factor: 0.968

2.  Analysis of randomized comparative clinical trial data for personalized treatment selections.

Authors:  Tianxi Cai; Lu Tian; Peggy H Wong; L J Wei
Journal:  Biostatistics       Date:  2010-09-28       Impact factor: 5.899

Review 3.  Trastuzumab--mechanism of action and use in clinical practice.

Authors:  Clifford A Hudis
Journal:  N Engl J Med       Date:  2007-07-05       Impact factor: 91.245

4.  Estimation and extrapolation of optimal treatment and testing strategies.

Authors:  James Robins; Liliana Orellana; Andrea Rotnitzky
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

5.  Doubly Robust Learning for Estimating Individualized Treatment with Censored Data.

Authors:  Y Q Zhao; D Zeng; E B Laber; R Song; M Yuan; M R Kosorok
Journal:  Biometrika       Date:  2015-03-01       Impact factor: 2.445

6.  Reinforcement learning design for cancer clinical trials.

Authors:  Yufan Zhao; Michael R Kosorok; Donglin Zeng
Journal:  Stat Med       Date:  2009-11-20       Impact factor: 2.373

7.  Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.

Authors:  Aleix Prat; Giampaolo Bianchini; Marlene Thomas; Anton Belousov; Maggie C U Cheang; Astrid Koehler; Patricia Gómez; Vladimir Semiglazov; Wolfgang Eiermann; Sergei Tjulandin; Mikhail Byakhow; Begoña Bermejo; Milvia Zambetti; Federico Vazquez; Luca Gianni; José Baselga
Journal:  Clin Cancer Res       Date:  2014-01-15       Impact factor: 12.531

8.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

Authors:  Luca Gianni; Wolfgang Eiermann; Vladimir Semiglazov; Alexey Manikhas; Ana Lluch; Sergey Tjulandin; Milvia Zambetti; Federico Vazquez; Mikhail Byakhow; Mikhail Lichinitser; Miguel Angel Climent; Eva Ciruelos; Belén Ojeda; Mauro Mansutti; Alla Bozhok; Roberta Baronio; Andrea Feyereislova; Claire Barton; Pinuccia Valagussa; Jose Baselga
Journal:  Lancet       Date:  2010-01-30       Impact factor: 79.321

9.  Supervised risk predictor of breast cancer based on intrinsic subtypes.

Authors:  Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

10.  Combining biomarkers to optimize patient treatment recommendations.

Authors:  Chaeryon Kang; Holly Janes; Ying Huang
Journal:  Biometrics       Date:  2014-05-30       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.